AR002704A1 - 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas. - Google Patents

2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.

Info

Publication number
AR002704A1
AR002704A1 ARP960101086A AR10108696A AR002704A1 AR 002704 A1 AR002704 A1 AR 002704A1 AR P960101086 A ARP960101086 A AR P960101086A AR 10108696 A AR10108696 A AR 10108696A AR 002704 A1 AR002704 A1 AR 002704A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
substituted
purin
alcoxifenil
onas
Prior art date
Application number
ARP960101086A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR002704A1 publication Critical patent/AR002704A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

2-(2-n-alcoxifenil)-purin-6-onas 9 sustituidas, y su procedimiento de preparación, que comprende ciclar los imidazoles correspondientementesustituidos y derivatizar las purinas así obtenidas. Las 2-(2-n-alcoxifenil) purin-6-onas 9-substituidas se pueden utilizar como compuestos activos encomposiciones farmacéuticas, en especial en composiciones farmacéutcas para el tratamiento de inflamaciones, enfermedades tromboembólicas, así comoenfermedades cardiovasculares.
ARP960101086A 1995-01-19 1996-01-19 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas. AR002704A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (1)

Publication Number Publication Date
AR002704A1 true AR002704A1 (es) 1998-04-29

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101086A AR002704A1 (es) 1995-01-19 1996-01-19 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.

Country Status (30)

Country Link
US (1) US5866571A (es)
EP (1) EP0722943A1 (es)
JP (1) JPH08231546A (es)
KR (1) KR960029335A (es)
CN (1) CN1138583A (es)
AR (1) AR002704A1 (es)
AU (1) AU4097796A (es)
BG (1) BG61729B1 (es)
BR (1) BR9600149A (es)
CA (1) CA2167349A1 (es)
CO (1) CO4700524A1 (es)
CZ (1) CZ16896A3 (es)
DE (1) DE19501480A1 (es)
EE (1) EE9600020A (es)
FI (1) FI960226A (es)
HR (1) HRP960009A2 (es)
HU (1) HUP9600107A3 (es)
IL (1) IL116771A (es)
MA (1) MA23779A1 (es)
NO (1) NO960221L (es)
NZ (1) NZ280829A (es)
PE (1) PE10597A1 (es)
PL (1) PL312353A1 (es)
SG (1) SG47379A1 (es)
SK (1) SK7696A3 (es)
SV (1) SV1996000004A (es)
TN (1) TNSN96005A1 (es)
TR (1) TR199600701A2 (es)
YU (1) YU2896A (es)
ZA (1) ZA96399B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
DE60222931T2 (de) * 2001-12-13 2008-07-10 Asubio Pharma Co., Ltd. Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
DE19501480A1 (de) 1996-07-25
IL116771A (en) 1999-06-20
KR960029335A (ko) 1996-08-17
YU2896A (sh) 1999-03-04
HUP9600107A3 (en) 1999-06-28
NZ280829A (en) 1998-04-27
IL116771A0 (en) 1996-05-14
EP0722943A1 (de) 1996-07-24
US5866571A (en) 1999-02-02
HU9600107D0 (en) 1996-03-28
CN1138583A (zh) 1996-12-25
CZ16896A3 (en) 1996-08-14
SG47379A1 (en) 1998-04-17
CA2167349A1 (en) 1996-07-20
BG61729B1 (bg) 1998-04-30
BR9600149A (pt) 1998-01-06
AU4097796A (en) 1996-07-25
SV1996000004A (es) 1997-02-19
NO960221L (no) 1996-07-22
MA23779A1 (fr) 1996-10-01
TNSN96005A1 (en) 2005-03-15
FI960226A (fi) 1996-07-20
PE10597A1 (es) 1997-06-13
TR199600701A2 (tr) 1996-08-21
CO4700524A1 (es) 1998-12-29
ZA96399B (en) 1996-08-14
HUP9600107A2 (en) 1997-05-28
PL312353A1 (en) 1996-07-22
NO960221D0 (no) 1996-01-18
JPH08231546A (ja) 1996-09-10
SK7696A3 (en) 1996-08-07
HRP960009A2 (en) 1997-12-31
BG100291A (bg) 1996-07-31
FI960226A0 (fi) 1996-01-17
EE9600020A (et) 1996-08-15

Similar Documents

Publication Publication Date Title
AR002704A1 (es) 2-(2-n-alcoxifenil)-purin-6-onas 9-sustituidas, procedimiento para su preparacion, composiciones farmaceuticas que las contienen y su uso parapreparar composiciones farmaceuticas.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR003220A1 (es) Derivados acilados de melatonina; composicion farmaceutica y cosmetica y el uso de los mismos para la preparacion de un medicamento.
SV1995000002A (es) Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
MX9102209A (es) Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
MX9400037A (es) Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
AU5877486A (en) Composition for the treatment of acne
ES2095662T3 (es) Derivados de imidazol con actividad antagonista de la angiotensina ii.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ECSP941120A (es) Derivados de 1,5 benzodiazepina
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
PT727996E (pt) Formulacoes de febbendazol
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2171743T3 (es) Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico.
ES2166838T3 (es) 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas.